Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Squamous Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Leukemia 1Esophageal Squamous Cell Carcinoma 1Epidermolysis Bullosa Dystrophica 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Imatinib Mesylate 86nilotinib 59fludarabine phosphate 46Cyclophosphamide 45Mycophenolic Acid 37Whole-Body Irradiation 35Dasatinib 32fludarabine 31Tacrolimus 29Cyclosporine 24Busulfan 23Peripheral Blood Stem Cell Transplantation 22Methotrexate 20bosutinib 18Cytarabine 18Granulocyte Colony-Stimulating Factor 16Filgrastim 16Melphalan 14thymoglobulin 13Antilymphocyte Serum 13Stem Cell Transplantation 12sargramostim 11Thiotepa 11Interferon-alpha 10Cord Blood Stem Cell Transplantation 9asciminib 8Cyclosporins 8ponatinib 7Sirolimus 7Radiotherapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × ON 01910 × Clear all
NCT00854646 2018-01-10

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Traws Pharma, Inc.

Phase 1 Completed
22 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01167166 2017-06-26

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Traws Pharma, Inc.

Phase 1/2 Completed
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡